BofA Initiates Viridian Therapeutics with Buy Rating on TED Drug Potential
BofA initiates Viridian Therapeutics (VRDN) with a Buy rating and $47 target. Lumvoa is positioned as a shorter-course rival to Amgen’s Tepezza in thyroid eye disease.
Already have an account? Sign in.